Press Releases
Disclosure of information required by AIM Rule 26
Northwest Biotherapeutics, Inc. (AIM: NWBT and NWBS; OTC BB: NWBT.US), the US based biotechnology company focused on the clinical development of immunotherapy products for cancer, announces that information required by AIM Rule 26 (Company Information Disclosure) is available on the Company’s investor relations website, http://www.nwbio.com/aim.php.
For further information, please contact:
Northwest Biotherapeutics
Lorie Calvo, Director of Operations |
+1 425-608-3008 |
Buchanan Communications
Lisa Baderoon (lisab@buchanan.uk.com)
/ Mary-Jane Johnson / Catherine Breen
|
+44 (0)20 7466 5000
|
|
